BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23218987)

  • 1. Is there a "gold" standard treatment for patients with isolated myeloid sarcoma?
    Antic D; Elezovic I; Milic N; Suvajdzic N; Vidovic A; Perunicic M; Djunic I; Mitrovic M; Tomin D
    Biomed Pharmacother; 2013 Feb; 67(1):72-7. PubMed ID: 23218987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
    Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma.
    Shimizu H; Saitoh T; Tanaka M; Mori T; Sakura T; Kawai N; Kanda Y; Nakaseko C; Yano S; Fujita H; Fujisawa S; Miyawaki S; Kanamori H; Okamoto S
    Leukemia; 2012 Dec; 26(12):2469-73. PubMed ID: 22699453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
    Kobos R; Steinherz PG; Kernan NA; Prockop SE; Scaradavou A; Small TN; Shukla N; Khalaf R; O'Reilly RJ; Boulad F
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):473-80. PubMed ID: 22079789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC.
    Chevallier P; Mohty M; Lioure B; Michel G; Contentin N; Deconinck E; Bordigoni P; Vernant JP; Hunault M; Vigouroux S; Blaise D; Tabrizi R; Buzyn A; Socie G; Michallet M; Volteau C; Harousseau JL
    J Clin Oncol; 2008 Oct; 26(30):4940-3. PubMed ID: 18606981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Graft clonogenicity and intensity of pre-treatment: factors affecting outcome of autologous peripheral hematopoietic cell transplantation in patients with acute myeloid leukemia in first remission.
    Strodtbeck D; Bornhäuser M; Hänel M; Lerche L; Schaich M; Illmer T; Thiede C; Geissler G; Herbst R; Ehninger G; Platzbecker U
    Bone Marrow Transplant; 2005 Dec; 36(12):1083-8. PubMed ID: 16247435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors for therapy-related acute myeloid leukaemia (t-AML)--a single centre experience.
    Suvajdžić N; Cvetković Z; Dorđević V; Kraguljac-Kurtović N; Stanisavljević D; Bogdanović A; Djunić I; Colović N; Vidović A; Elezović I; Tomin D
    Biomed Pharmacother; 2012 Jun; 66(4):285-92. PubMed ID: 22401928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma.
    Avni B; Rund D; Levin M; Grisariu S; Ben-Yehuda D; Bar-Cohen S; Paltiel O
    Hematol Oncol; 2012 Mar; 30(1):34-40. PubMed ID: 21638303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
    Tsimberidou AM; Kantarjian HM; Estey E; Cortes JE; Verstovsek S; Faderl S; Thomas DA; Garcia-Manero G; Ferrajoli A; Manning JT; Keating MJ; Albitar M; O'Brien S; Giles FJ
    Leukemia; 2003 Jun; 17(6):1100-3. PubMed ID: 12764375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathologic analysis of extramedullary tumors after hematopoietic stem cell transplantation.
    Huang Q; Reddi D; Chu P; Snyder DS; Weisenburger DD
    Hum Pathol; 2014 Dec; 45(12):2404-10. PubMed ID: 25294373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors of treatment outcomes in patients with granulocytic sarcoma.
    Lan TY; Lin DT; Tien HF; Yang RS; Chen CY; Wu K
    Acta Haematol; 2009; 122(4):238-46. PubMed ID: 19887783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.
    Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V
    J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes for patients with chloroma receiving radiation therapy.
    Hall MD; Chen YJ; Schultheiss TE; Pezner RD; Stein AS; Wong JY
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):523-7. PubMed ID: 24649928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Remission following Autologous Hematopoietic Cell Transplantation in a Patient with Multiple Nonleukemic Myeloid Sarcoma and a Review of the Literature.
    Liang Y; Gao J; Wu D; Li S; Chen H; Ding L; Tong J; Xu Y
    Acta Haematol; 2017; 137(3):117-122. PubMed ID: 28301836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.
    Fouillard L; Labopin M; Gratwohl A; Gluckman E; Frassoni F; Beelen DW; Willemze R; Montserrat E; Blaise D; Atienza AI; Sierra J; Santos M; Gorin NC; Rocha V;
    Haematologica; 2008 Jun; 93(6):834-41. PubMed ID: 18469352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
    Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
    Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.